UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Keryx Biopharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
492515101
(CUSIP Number)
December 31, 2009
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
----------------
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934 ("Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 7 Pages
CUSIP No. 492515101 13G Page 2 of 7 Pages
-------------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS
Hartz Capital Investments, LLC
-------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [X]
(b) [ ]
-------------------------------------------------------------------------------
(3) SEC USE ONLY
-------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
-------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ----------------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
Warrants to purchase 1,470,000 shares of Common Stock
OWNED BY ----------------------------------------------------------------
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ----------------------------------------------------------------
PERSON WITH: (8) SHARED DISPOSITIVE POWER
Warrants to purchase 1,470,000 shares of Common Stock
-------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
Warrants to purchase 1,470,000 shares of Common Stock
-------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
[ ]
-------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
2.56%
-------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (see instructions)
OO
-------------------------------------------------------------------------------
CUSIP No. 492515101 13G Page 3 of 7 Pages
-------------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS
Empery Asset Management, LP
-------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) [X]
(b) [ ]
-------------------------------------------------------------------------------
(3) SEC USE ONLY
-------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ----------------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
Warrants to purchase 931,000 shares of Common Stock
OWNED BY ----------------------------------------------------------------
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ----------------------------------------------------------------
PERSON WITH: (8) SHARED DISPOSITIVE POWER
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
[ ]
-------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.64%
-------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (see instructions)
PN
-------------------------------------------------------------------------------
CUSIP No. 492515101 13G Page 4 of 7 Pages
-------------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS
Ryan M. Lane
-------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [X]
(b) [ ]
-------------------------------------------------------------------------------
(3) SEC USE ONLY
-------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
-------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ----------------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
Warrants to purchase 931,000 shares of Common Stock
OWNED BY ----------------------------------------------------------------
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ----------------------------------------------------------------
PERSON WITH: (8) SHARED DISPOSITIVE POWER
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
[ ]
-------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.64%
-------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (see instructions)
IN
-------------------------------------------------------------------------------
CUSIP No. 492515101 13G Page 5 of 7 Pages
-------------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS
Martin D. Hoe
-------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [X]
(b) [ ]
-------------------------------------------------------------------------------
(3) SEC USE ONLY
-------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
-------------------------------------------------------------------------------
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ----------------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
Warrants to purchase 931,000 shares of Common Stock
OWNED BY ----------------------------------------------------------------
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ----------------------------------------------------------------
PERSON WITH: (8) SHARED DISPOSITIVE POWER
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
Warrants to purchase 931,000 shares of Common Stock
-------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
[ ]
-------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.64%
-------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (see instructions)
IN
-------------------------------------------------------------------------------
CUSIP No. 492515101 13G Page 6 of 7 Pages
This Amendment No. 1 (this "Amendment") amends the statement on Schedule 13G
filed on October 1, 2009 (the "Original Schedule 13G" and the Original Schedule
13G as amended, the "Schedule 13G") with respect to shares of common stock,
$0.001 par value per share (the "Common Stock") of Keryx Biopharmaceuticals,
Inc., a Delaware corporation (the "Company"). Capitalized terms used herein and
not otherwise defined in this Amendment have the meanings set forth in the
Schedule 13G. This Amendment amends and restates Items 4 and 5 in their entirety
as set forth below.
Item 4. Ownership
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
The information as of the filing date required by Items 4(a) - (c) is set forth
in Rows 5 - 11 of the cover page for each Reporting Person hereto and is
incorporated herein by reference for each such Reporting Person. The Company's
quarterly report for the quarterly period ended September 30, 2009 filed on Form
10-Q on November 10, 2009, indicates that as of November 9, 2009, there were
55,980,530 shares of Common Stock outstanding. Pursuant to the terms of the
Warrants, the Empery Funds cannot exercise any of the Warrants until such time
as the Reporting Persons would not beneficially own, after any such exercise,
more than 4.99% of the outstanding number of shares of Common Stock (the
"Blocker"). The percentage set forth on Row (11) of the cover pages reflects the
Reporting Persons' beneficial ownership of shares of Common Stock of the Company
as of December 31, 2009 and is calculated based on the total number of
outstanding shares of Common Stock and assumes the exercise of the reported
Warrants.
The Investment Manager, which serves as the investment manager to the Empery
Funds, may be deemed to be the beneficial owner of all shares of Common Stock
owned by the Empery Funds. Each of the Reporting Individuals, as Managing
Members of the General Partner of the Investment Manager with the power to
exercise investment discretion, may be deemed to be the beneficial owner of all
shares of Common Stock owned by the Empery Funds. Each of the Investment Manager
and the Reporting Individuals hereby disclaims any beneficial ownership of any
such shares of Common Stock, except for their pecuniary interest therein.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following: [X]
CUSIP No. 492515101 13G Page 7 of 7 Pages
SIGNATURES
After reasonable inquiry and to the best of its knowledge and
belief, each of the undersigned certifies that the information with respect to
it set forth in this statement is true, complete, and correct.
Dated: February 12, 2010
EMPERY ASSET MANAGEMENT, LP HARTZ CAPITAL INVESTMENTS LLC
By: EMPERY AM GP, LLC, its General By: EMPERY ASSET MANAGEMENT, LP, its
Partner Authorized Agent
By: EMPERY AM GP, LLC, its General
By: /s/ Ryan M. Lane Partner
----------------------
Name: Ryan M. Lane
Title: Managing Member By: /s/ Ryan M. Lane
-----------------------
Name: Ryan M. Lane
Title: Managing Member
/s/ Martin D. Hoe /s/ Ryan M. Lane
---------------------- -----------------------
Martin D. Hoe Ryan M. Lane